False-positive mammograms may result in women delaying their next screening mammogram.
Women who receive a false-positive mammogram are more likely to delay subsequent screenings compared with women who have true negative mammograms, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
Researchers from the University of Illinois at Chicago undertook the study to examine the impact of a false-positive screening mammogram on subsequent screening mammography behavior, such as a delay of more than 12 months from index mammogram to the next one, and resulting cumulative risk.
Data from 741,150 screening mammograms from 261,767 women were obtained through a large health care organization with multiple facilities in the greater metropolitan Chicago area. Of these mammograms, 12.3% (90,918 exams) yielded a false positive result, the remaining 87.7% (650,232 exams) yielded true negative results.
The results from the database showed that receiving a false-positive mammogram did result in delays for subsequent screening:
*This difference was statistically significant.
"Because we obtained the same conclusion using two different statistical approaches to analyze the data, we have a high degree of confidence in the results," Firas M. Dabbous, PhD, manager of patient centered outcomes research at the Russell Institute for Research & Innovation at the Advocate Lutheran General Hospital in Park Ridge, Illinois, said in a release. "We believe that the delay in subsequent screening for women who have an initial false positive result increases the probability that they will subsequently receive a later-stage breast cancer diagnosis compared with women who first have a true negative result from a screening mammogram."
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.